Results
1 -
10 of
30Pike Andy, Storer R. Ian, Owen Robert M., Armstrong Emma, Benn Caroline L., Bictash Magda, Cheung Kathy F. K., Costelloe Kathryn, Dardennes Emmanuel, Impey Emma, Milliken Philip H., Mortimer-Cassen Elisabeth, Pearce Hannah J..
The design, synthesis and evaluation of low molecular weight acidic sulfonamides as URAT1 inhibitors for the treatment of gout, Med. Chem. Commun., 2016 Storer R. Ian, Owen Robert M., Pike Andy, Benn Caroline L., Armstrong Emma, Blakemore David C., Bictash Magda, Costelloe Kathryn, Impey Emma, Milliken Philip H., Mortimer-Cassen Elisabeth, Pearce Hannah J., Pibworth Benjamin, Toschi Gianna.
The discovery and evaluation of diaryl ether heterocyclic sulfonamides as URAT1 inhibitors for the treatment of gout, Med. Chem. Commun., 2016 Acute kidney injury observed during phase 1 clinical trials of a novel xanthine oxidase/URAT1 dual inhibitor PF-06743649, Clinical Rheumatology Evaluation and Treatment of Gout as a Chronic Disease, Advances in Therapy Gout: will the u201cKing of Diseasesu201d be the first rheumatic disease to be cured?, BMC Medicine Inflammasom und Gicht, Zeitschrift f??r Rheumatologie Crystal arthritides u2013 gout and calcium pyrophosphate arthritis, Zeitschrift f??r Gerontologie und Geriatrie New Agents for the Treatment of Gout and Hyperuricemia: Febuxostat, Puricase, and Beyond, Current Rheumatology Reports What Is the Evidence for Treat-to-Target Serum Urate in Gout?, Current Rheumatology Reports New and Pipeline Drugs for Gout, Current Rheumatology Reports